Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests

被引：13
作者：
Barry A.L. [1 ]
Fuchs P.C. [1 ]
Brown S.D. [1 ]
机构：
[1] Clinical Microbiology Institute, Wilsonville, OR 97070
来源：
European Journal of Clinical Microbiology and Infectious Diseases | 1999年 / 18卷 / 4期
关键词：
Levofloxacin; Moxifloxacin; Streptococcus Pneumoniae; Haemophilus Influenzae; Broth Microdilution;
D O I：
10.1007/s100960050284
中图分类号：
学科分类号：
摘要：
Moxifloxacin (Bay 12-8039), ciprofloxacin, and levofloxacin were compared in vitro against 1074 clinical isolates gathered from different medical centers throughout North America during the winter months of 1997. Moxifloxacin E tests and broth microdilution tests gave compatable results. Moxifloxacin was particularly potent against respiratory pathogens such as Haemophilus influenzae and Streptococcus pneumoniae. Ciprofloxacin was the most potent study drug against the family of Enterobacteriaceae and Pseudonmoniae spp. For tests of 5 μg moxifloxacin disks, zone size criteria of ≤ 17 mm for resistant (MIC ≥ 8 μg/ml) and ≥ 21 mm for susceptible (MIC ≤ 2 μg/ml) are provisionally proposed for use while clinical trials are under way.
引用
收藏
页码：305 / 309
页数：4
相关论文
共 11 条
  • [1] Brueggemann A.B., Kugler K.C., Doern G.V., In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis, Antimicrobial Agents and Chemotherapy, 41, pp. 1594-1597, (1997)
  • [2] Fass R.J., In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, Antimicrobial Agents and Chemotherapy, 41, pp. 1818-1824, (1997)
  • [3] Visalli M.A., Jacobs M.R., Applebaum P.C., Antipneumococcal activity of BAY 12-8039, a new quinolone, compared with activities of three other quinolones and four oral β-lactams, Antimicrobial Agents and Chemotherapy, 41, pp. 2786-2789, (1997)
  • [4] Woodcock J.M., Andrews J.M., Boswell F.J., Brenwald N.P., Wise R., In vitro activity of Bay 12-8039, a new fluoroquinolone, Antimicrobial Agents and Chemotherapy, 41, pp. 101-106, (1997)
  • [5] Aldridge K.E., Ashcraft D.H., Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes, Antimicrobial Agents and Chemotherapy, 41, pp. 709-711, (1997)
  • [6] Goldstein E.J.C., Citron D.M., Hudspeth M., Gerarda S.H., Merriam C.V., In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans, Antimicrobial Agents and Chemotherapy, 41, pp. 1552-1557, (1997)
  • [7] Boswell F.J., Andrews J.M., Wise R., Pharmacodynamic properties of BAY 12-8039 on gram-positive and gram-negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effect, Antimicrobial Agents and Chemotherapy, 41, pp. 1377-1379, (1997)
  • [8] Performance standards for antimicrobial disk susceptibility tests, Approved Standard M2-a6, (1997)
  • [9] Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, Approved Standard M7-A4, (1997)
  • [10] Thornsberry C., Ogilvie P., Kahn J., Mauriz Y., Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzas, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season, Diagnostic Microbiology and Infectious Disease, 29, pp. 249-257, (1997)
12